Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England

作者：Howell Jones R; Bailey A; Beddows S; Sargent A; de Silva N; Wilson G; Anton J; Nichols T; Soldan K^*; Kitchener H

来源：British Journal of Cancer, 2010, 103(2): 209-216.

DOI：10.1038/sj.bjc.6605747

• human papillomavirus (HPV)
• cervical cancer
• cervical screening
• immunisation

BACKGROUND: Knowledge of the prevalence of type-specific human papillomavirus (HPV) infections is necessary to predict the expected, and to monitor the actual, impact of HPV immunisation and to design effective screening strategies for vaccinated populations.
METHODS: Residual specimens of cervical cytology (N = 4719), CIN3/CGIN and cervical cancer biopsies (N = 1515) were obtained from sites throughout England, anonymised and tested for HPV DNA using the Linear Array typing system (Roche).
RESULTS: The prevalence of HPV 16 and/or 18 (with or without another high-risk (HR) type) was 76% in squamous cell carcinomas, 82% in adeno/adenosquamous carcinomas and 63% and 91% in CIN3 and CGIN, respectively. Of all HR HPV-infected women undergoing cytology, non-vaccine HPV types only were found in over 60% of those with mild dyskaryosis or below, and in <20% of those with cancer. In women of all ages undergoing screening, HR HPV prevalence was 16% and HPV 16 and/or 18 prevalence was 5%.
CONCLUSION: Pre-immunisation, high-grade cervical disease in England was predominantly associated with HPV 16 and/or 18, which promises a high impact from HPV immunisation in due course. Second-generation vaccines and screening strategies need to consider the best ways to detect and prevent disease due to the remaining HR HPV types. British Journal of Cancer (2010) 103, 209-216. doi: 10.1038/sj.bjc.6605747 www.bjcancer.

• 出版日期2010-7-13